The Readout LOUD

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come. Subscribe today on iTunes, Spotify, SoundCloud, and Stitcher.

All Coverage

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture

The Readout LOUD Damian Garde and Meg Tirrell

Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: SVB’s long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: The return of bird flu and the effects of pandemic fatigue

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Pharma blockbusters, pandemic policy, & legal chicanery

The Readout LOUD Adam Feuerstein and Meg Tirrell

Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

The ‘electric vehicles’ of pharma, Illumina’s boondoggle, & a Theranos sentencing

The Readout LOUD Adam Feuerstein, Damian Garde and Allison DeAngelis

Listen: Whither PhRMA, Alzheimer’s treatment data revealed, and the first fecal microbiome drug approval

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Roche’s failure, Eisai’s success, and a live AMA

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Biogen’s new CEO, how the midterms affect science, & a biotech bankruptcy

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: How the biotech revolution could come apart at the seams

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

BU’s Covid tinkering, FDA on trial, & why it’s hard to take drugs off the market

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

BIO’s messy transition, mRNA’s future, & Biogen’s next CEO

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Nobels for science, biotech dealmaking, & a friendly FTC

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Most Read

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

Listen: Sarepta’s pivotal moment, biotech’s big week, & the future of Covid boosters

Listen: The next CRISPR fight, cheaper insulin, & an FDA shuffle

STAT Plus: Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more

Listen: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers

Listen: Vas Narasimhan on the future of pharma, plus Moderna’s vaccine promise & a biotech presidential bid

Listen: Vertex vs. insurers, Moderna’s future, & biotech’s long winter

Listen: How the legal battle over abortion could thwart research, plus: the FDA ‘bully pulpit’ and Moderna’s future

All Coverage

Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture

Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster

Listen: SVB’s long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

Listen: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

Listen: The return of bird flu and the effects of pandemic fatigue

Listen: Pharma blockbusters, pandemic policy, & legal chicanery

Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection

Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score

#JPM23 in review, the year ahead, & the merits of Miami

Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants

2022 in review, CEO indictments, & the year ahead

Listen: Leaky health data, ASH22, & what it takes to get booed by your peers

The ‘electric vehicles’ of pharma, Illumina’s boondoggle, & a Theranos sentencing

Listen: Whither PhRMA, Alzheimer’s treatment data revealed, and the first fecal microbiome drug approval

Listen: Roche’s failure, Eisai’s success, and a live AMA

Listen: Biogen’s new CEO, how the midterms affect science, & a biotech bankruptcy

Listen: How the biotech revolution could come apart at the seams

Listen: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

BU’s Covid tinkering, FDA on trial, & why it’s hard to take drugs off the market

BIO’s messy transition, mRNA’s future, & Biogen’s next CEO

Listen: Nobels for science, biotech dealmaking, & a friendly FTC

Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy

Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0

Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred

Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day

Subscribe to STAT+ for less than $2 per day

Become a STAT+ subscriber today!